Capricor Therapeutics - Company & Market Research Reports

Capricor Therapeutics focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 and enderitide, which are in Phase II clinical trials. It is also developing Exosomes for the treatment of cardiovascular and non-cardiovascular diseases. The company was founded in 2005 and is headquartered in Beverly Hills, California.